Low frequency of drug-resistant virus did not affect the therapeutic eficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV ge notype-1infection

Antiviral Therapy

Volumn 21, Issue 1, 2016, Pages 37-44

  Kinugasa, Hideaki ^a   Ikeda, Fusao ^a   Takaguchi, Kouichi ^b   Mori, Chizuru ^a   Matsubara, Takehiro ^c   Shiraha, Hidenori ^a   Takaki, Akinobu ^a   Iwasaki, Yoshiaki ^a   Toyooka, Shinichi ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASUNAPREVIR; ASUNAPREVIR PLUS DACLATASVIR; DACLATASVIR; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; INTERFERON; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BIOLOGICAL MARKER; BMS-790052; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE; VIRAL PROTEIN;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIRECT SEQUENCING; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; MALE; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; RNA SYNTHESIS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; AMINO ACID SUBSTITUTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; RETREATMENT; TIME FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BIOMARKERS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETREATMENT; SULFONAMIDES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84964681423     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2976     Document Type: Article

References (16)

1. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
2. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
3. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
4. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
5. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-748.
6. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58:655-662.
7. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59:2083-2091.
8. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013;58:646-654.
9. Kosaka K, Imamura M, Hayes CN, et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat 2015;22:158-165.
10. Tadokoro K, Suzuki F, Kobayashi M, et al. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay. J Virol Methods 2011;171:67-73.
11. Tadokoro K, Suzuki F, Kobayashi M, et al. Rapid and high sensitive detection of Y93H amino acid substitution in HCV NS5A region using the PCR-Invader assay. Kanzo 2014;55:720-722.
12. Kan T, Hashimoto S, Kawabe N, et al. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. J Gastroenterol 2015; in press.
13. Preciado M V, Valva P, Escobar-Gutierrez A, et al. Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. World J Gastroenterol 2014;20:15992-16013.
14. Maimone S, Tripodi G, Musolino C, Cacciola I, Pollicino T, Raimondo G. Lack of the NS5B S282T mutation in HCV isolates from liver tissue of naive patients with HCV genotype-1b infection. Antivir Ther 2015;20:245-247.
15. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010;54:3641-3650.
16. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013;11:482-496.